SCHOTT Pharma stock
Price history
+21.45% over the period1 year: from €18.32 (November 20, 2025) to €22.25 (November 20, 2026), +21.45%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €22.25 |
| October 30, 2026 | €25.00 |
| September 30, 2026 | €24.95 |
| August 31, 2026 | €23.15 |
| July 31, 2026 | €21.95 |
| June 30, 2026 | €17.30 |
| May 29, 2026 | €18.20 |
| April 30, 2026 | €14.94 |
| March 31, 2026 | €13.52 |
| February 27, 2026 | €14.78 |
| January 30, 2026 | €14.36 |
| December 30, 2025 | €15.10 |
| November 28, 2025 | €19.12 |
| November 20, 2025 | €18.32 |
At a glance
The company
Develops, manufactures and sells drug containment solutions and delivery systems for injectable drugs for the pharma, biotech and life science industries
Latest results
Quarter to June 30, 2026 · EPS €0.26 (estimate €0.25)
Next event
TickerLandia's take on SCHOTT Pharma
- Priced in line with similar companies: trailing 12-month P/E 25 vs 25 (+0%) in a group of 9.
- Strong point: Earnings stability (79/100 in its group). Weak point: Dividend (17/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−15.08% from the 52-week high
Analysts · 13 analysts
Average target€25.03+12.50% vs. price
Buy 8 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: SCHOTT Pharma
Compared with similar companies: very low dividend.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage44
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 25.1 32 Forward P/E 20.6 49 Price/book 3.39 49 Price/sales 3.35 54 EV/EBITDA 14.7 37 Profitabilityaverage51
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 16.4% 57 ROE 14.7% 63 ROA 6.5% 57 Gross margin 31.2% 7 Net margin 13.4% 69 Earnings stabilityhigh79
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Margin variabilitycounts in reverse: lower means more earnings stability 1.0% 96 Growthaverage50
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +10.00% 75 Earnings growth (year over year) −13.30% 19 Average revenue growth (3 years) +6.30% 57 Financial strengthaverage59
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.31 62 Current ratio 1.61 43 Interest coverage 9.64 68 Net debt/EBITDAcounts in reverse: lower means more financial strength 0.23 64 Dividendvery low17
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 3 years 13 Dividend yield 0.8% 24 Payout ratio 20.0% 15 Market momentumstrong77
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +21.45% 68 Distance from 200-day average +16.18% 90 Relative strength (3 months) +2.46% 54 Relative strength (6 months) +33.68% 95 Riskaverage57
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.6% 61 Beta (1 year) 0.61 37 Maximum drawdown (12 months) 32.2% 73
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
SCHOTT Pharma is in line with similar companies
SCHOTT Pharma's P/E (trailing 12 months): 25.1, in line with the median of a group of 9 similar companies (25.1).
Compared with 9 similar companies
| Metric | SCHOTT Pharma | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 25.1 | Middle | |
| Forward P/E | 20.6 | Middle | |
| Operating margin | 16.4% | Middle | |
| ROE | 14.7% | Middle | |
| Debt/equity | 0.31 | Middle |
Grey band: the middle half of the group; tick: the median; dot: SCHOTT Pharma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€281.76M
Latest quarter · Q2 2026
Net income
€38.83M
Latest quarter · Q2 2026
Quarterly net margin
13.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €3.4B
- P/E
- 25.1
- EPS
- €0.90
- Volume
- 33.62K
- Daily trading
- €2.23M
- Dividend yield
- 0.81%
- Last ex-dividend on February 4, 2026
How SCHOTT Pharma is changing
All resultsRevenue grew 11.0% a year on average over the last 5 years
Operating margin fell from 20.5% to 18.8%
Less cash than profit: free cash flow equal to 27% of net income
Returns
SCHOTT Pharma returns with dividends
€1,000 invested in SCHOTT Pharma 3 years ago, on November 20, 2023, would be worth €820 today with dividends reinvested: −18.03% in total, −6.41% per year. On price alone it would be €801 (−19.91%).
| Period | SCHOTT Pharma | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | −14.42% | −1.98% | €856 |
| 6 months | +34.04% | +0.26% | €1,340 |
| Year to date | +47.35% | +1.28% | €1,474 |
| 1 year | +23.00% | +6.55% | €1,230 |
| 3 years | −18.03% | +55.98% | €820 |
Over the last 6 months it has done better than 70% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
SCHOTT Pharma: technical analysis
SCHOTT Pharma shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 46.0% below its all-time closing high (€41.20, March 20, 2024).
- Trend
- No clear trend
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- +16.18%
Support and resistance
Price areas where SCHOTT Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€26.13+17.42%2 touches, last on October 21, 2026
- Resistance€23.18+4.16%2 touches, last on October 9, 2026
- Last price€22.25
- Support€21.68−2.58%2 touches, last on September 7, 2026
- Support€19.80−11.00%3 touches, last on November 9, 2026
- Support€18.17−18.34%2 touches, last on June 15, 2026
Volatility and risk
Over the last year it has moved less than the DAX.
- Beta (1 year) vs DAX
- 0.61
- Volatility (60 sessions, annualised)
- 30.6%
- Largest fall in the last year
- −32.22%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
SCHOTT Pharma and its competitors
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide.
- Headquarters
- Mainz, Germany
- Employees
- 5,002
- Founded
- 1884
- Chief executive
- Christian Mias
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| SCHOTT Pharma1SXP | $3.74B | 16.4% | 25.1 | +34.04% |
| Tecan GroupTECN | $3.58B | 4.9% | — | +64.44% |
| Fielmann GroupFIE | $3.93B | 13.7% | 16.4 | −3.95% |
| Carl Zeiss MeditecAFX | $3.07B | 7.2% | 23.3 | +24.32% |
| OttobockOBCK | $2.68B | 18.7% | 19.0 | −31.33% |
| AddLifeALIF.B | $2.11B | 8.9% | 33.5 | +17.73% |
Same industry or related industries, similar size. Compare SCHOTT Pharma with its competitors · Full profile